IP Library › Granted Patent US 12,336,989
Granted Patent B2
US 12,336,989 · App. 18/476,138 · Granted Jun 24, 2025

Transmucosal methods for treating psychiatric and neurological conditions

Inventors: Peng Li (New Milford, NJ); Wei Yao (New Milford, NJ); Robert Davis (San Diego, CA)
Assignee: INTRA-CELLULAR THERAPIES, INC.
A61K31/4985A61K9/0036A61K9/0043A61K9/006A61K9/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,336,989
App. No.
18/476,138
Granted
Jun 24, 2025
Kind
B2
Abstract

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d 4 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Claims (33)

1. A transmucosal pharmaceutical formulation comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula II) in tosylate salt form; wherein the formulation is a rapidly dissolving tablet or wafer, or a sublingual tablet or wafer, and wherein the formulation comprises from 0.01 to 30 mg of the Compound of Formula II (free base equivalent).

2. The formulation of claim 1 , wherein the formulation comprises from 0.01 to 10 mg of the Compound of Formula II (free base equivalent).

3. The formulation of claim 1 , wherein the formulation comprises from 10 to 30 mg of the Compound of Formula II (free base equivalent).

4. The formulation of claim 1 , wherein the formulation is absorbed by the mucosa or dissolves in less than 30 seconds after administration.

5. The formulation of claim 1 , wherein the formulation further comprises one or more excipients selected from the group consisting of plasticizers, surfactants, drying agents, flavors, sweeteners, binders, disintegrants, humectants, wetting agents, antioxidants, buffering agents, and thickening agents.

6. The formulation of claim 5 , wherein the one or more excipients comprise one or more gums, polysaccharides, polysaccharide derivatives, gelatins, synthetic polymers, sugars, sugar alcohols, or any combination thereof.

7. The formulation of claim 1 , wherein the formulation further comprises one or more excipients selected from carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, bovine gelatin, porcine gelatin, avian gelatin, fish gelatin, dextrose, lactose, galactose, glucose, ribose, sucrose, trehalose, mannitol, maltitol, lactitol, sorbitol, xylitol, erythritol, galactitol, and inositol, or any combination thereof.

8. The formulation of claim 7 , wherein the formulation further comprises one or more excipients selected from bovine gelatin, porcine gelatin, avian gelatin, fish gelatin, mannitol, maltitol, lactitol, sorbitol, xylitol, erythritol, galactitol, and inositol, or any combination thereof.

9. The formulation of claim 8 , wherein the formulation further comprises one or more fish gelatins and mannitol.

10. The formulation of claim 8 , wherein the one or more fish gelatins comprise a mixture of high molecular weight and low molecular weight fish gelatins.

11. The formulation of claim 10 , wherein the formulation comprises from 0.01 to 10 mg of the Compound of Formula II (free base equivalent).

12. The formulation of claim 10 , wherein the formulation comprises from 10 to 30 mg of the Compound of Formula II (free base equivalent).

13. The formulation of claim 1 , wherein the formulation comprises from 5 to 20 mg of the Compound of Formula II (free base equivalent).

14. The formulation of claim 1 , wherein the formulation comprises from 0.05 to 8 mg of the Compound of Formula II (free base equivalent).

15. The formulation of claim 10 , wherein the formulation comprises from 5 to 20 mg of the Compound of Formula II (free base equivalent).

16. The formulation of claim 10 , wherein the formulation comprises from 0.05 to 8 mg of the Compound of Formula II (free base equivalent).

17. A method for the prophylaxis or treatment of a disease or abnormal condition involving or mediated by the 5-HT 2A receptor, serotonin transporter (SERT), and/or dopamine D 1 /D 2 receptor signaling pathways, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the formulation of claim 1 , wherein the disease or abnormal condition is selected from the group consisting of obesity, anorexia, bulimia, depression, major depressive disorder (MDD), anxiety, psychosis, schizophrenia, obsessive-compulsive disorder, sexual disorders, migraine, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, conditions associated with cephalic pain, social phobias, dementia, Alzheimer's Disease, Parkinson's dementia, and bipolar disorder.

18. The method of claim 17 , wherein the disease or abnormal condition is selected from the group consisting of depression, major depressive disorder (MDD), anxiety, psychosis, schizophrenia, and bipolar disorder.

19. The method of claim 17 , wherein the disease or abnormal condition is selected from the group consisting of obsessive-compulsive disorder, attention deficit disorder, and attention deficit hyperactivity disorder.

20. The method of claim 17 , wherein the formulation further comprises one or more excipients selected from carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, bovine gelatin, porcine gelatin, avian gelatin, fish gelatin, dextrose, lactose, galactose, glucose, ribose, sucrose, trehalose, mannitol, maltitol, lactitol, sorbitol, xylitol, erythritol, galactitol, and inositol, or any combination thereof.

21. The method of claim 20 , wherein the formulation further comprises one or more excipients selected from bovine gelatin, porcine gelatin, avian gelatin, fish gelatin, mannitol, maltitol, lactitol, sorbitol, xylitol, erythritol, galactitol, and inositol, or any combination thereof.

22. The method of claim 21 , wherein the formulation further comprises one or more fish gelatins and mannitol.

23. The method of claim 22 , wherein the one or more fish gelatins comprise a mixture of high molecular weight and low molecular weight fish gelatins.

24. The method of claim 23 , wherein the formulation comprises from 0.01 to 10 mg of the Compound of Formula II (free base equivalent).

25. The method of claim 23 , wherein the formulation comprises from 10 to 30 mg of the Compound of Formula II (free base equivalent).

26. The method of claim 23 , wherein the formulation comprises from 5 to 20 mg of the Compound of Formula II (free base equivalent).

27. A transmucosal pharmaceutical formulation comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d 2 -3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (Compound of Formula II) in tosylate salt form; wherein the formulation is a rapidly dissolving tablet or wafer, or a sublingual tablet or wafer, and wherein the formulation comprises from 0.01 to 30 mg of the Compound of Formula II (free base equivalent); and wherein the formulation further comprises one or more fish gelatins.

28. The formulation according to claim 27 , wherein the formulation further comprises one or more excipients selected from bovine gelatin, porcine gelatin, avian gelatin, mannitol, maltitol, lactitol, sorbitol, xylitol, erythritol, galactitol, and inositol, or any combination thereof.

29. The formulation according to claim 28 , wherein the formulation further comprises mannitol.

30. The formulation according to claim 29 , wherein the one or more fish gelatins comprise a mixture of high molecular weight and low molecular weight fish gelatins.

31. The formulation of claim 30 , wherein the formulation is absorbed by the mucosa or dissolves in less than 30 seconds after administration.

32. A method for the treatment of a disease or abnormal condition involving or mediated by the 5-HT 2A receptor, serotonin transporter (SERT), and/or dopamine D 1 /D 2 receptor signaling pathways, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the formulation of claim 27 , wherein the disease or abnormal condition is selected from the group consisting of depression, major depressive disorder (MDD), anxiety, psychosis, schizophrenia, dementia, Alzheimer's Disease, and bipolar disorder.

33. The method according to claim 32 , wherein the Compound of Formula II is administered sublingually.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2023
From: DAVIS, ROBERT; YAO, WEI; LI, PENG
To: INTRA-CELLULAR THERAPIES, INC.
Reel/Frame 065055/0174 →
Continuity (6)
Continuation 18319425 · May 17, 2023
Continuation 17338573 · Jun 3, 2021
Continuation 16900746 · Jun 12, 2020
Continuation 15934860 · Mar 23, 2018
Provisional Application 62476538 · Mar 24, 2017
Related Publication 20240016802A1 · Jan 18, 2024
References Cited (371)
US 2490813A · Hughes et al. · 1949 [cited by applicant]
US 3299078A · Pachter · 1967 [cited by applicant]
US 3813392A · Sellstedt et al. · 1974 [cited by applicant]
US 3914421A · Rajagopalan · 1975 [cited by applicant]
US 4001263A · Plattner et al. · 1977 [cited by applicant]
US 4115577A · Rajagopalan · 1978 [cited by applicant]
US 4136145A · Fuchs et al. · 1979 [cited by applicant]
US 4183936A · Rajagopalan · 1980 [cited by applicant]
US 4219550A · Rajagopalan · 1980 [cited by applicant]
US 4238607A · Rajagopalan · 1980 [cited by applicant]
US 4389330A · Tice et al. · 1983 [cited by applicant]
US 4522944A · Doria et al. · 1985 [cited by applicant]
US 4530840A · Tice et al. · 1985 [cited by applicant]
US 4849246A · Schmidt · 1989 [cited by applicant]
US 4971971A · Tokunaga et al. · 1990 [cited by applicant]
US 4985432A · Tokunaga et al. · 1991 [cited by applicant]
US 5114976A · Norden · 1992 [cited by applicant]
US 5151419A · Perenyi et al. · 1992 [cited by applicant]
US 5538739A · Bodmer et al. · 1996 [cited by applicant]
US 5576460A · Buchwald et al. · 1996 [cited by applicant]
US 5629003A · Horstmann et al. · 1997 [cited by applicant]
US 5648539A · Goodbrand · 1997 [cited by applicant]
US 5648542A · Goodbrand et al. · 1997 [cited by applicant]
US 5654482A · Goodbrand · 1997 [cited by applicant]
US 5705697A · Goodbrand et al. · 1998 [cited by applicant]
US 5723669A · Goodbrand et al. · 1998 [cited by applicant]
US 5723671A · Goodbrand et al. · 1998 [cited by applicant]
US 5763476A · Delbressine et al. · 1998 [cited by applicant]
US 5847166A · Buchwald et al. · 1998 [cited by applicant]
US 5902901A · Goodbrand et al. · 1999 [cited by applicant]
US 5948430A · Zerbe et al. · 1999 [cited by applicant]
US 6043370A · Kubo et al. · 2000 [cited by applicant]
US 6166226A · Buchwald et al. · 2000 [cited by applicant]
US 6221335B1 · Foster · 2001 [cited by applicant]
US 6235936B1 · Buchwald et al. · 2001 [cited by applicant]
US 6307087B1 · Buchwald et al. · 2001 [cited by applicant]
US 6323366B1 · Wolfe et al. · 2001 [cited by applicant]
US 6395916B1 · Buchwald et al. · 2002 [cited by applicant]
US 6407092B1 · Hester et al. · 2002 [cited by applicant]
US 6440710B1 · Keinan et al. · 2002 [cited by applicant]
US 6465693B2 · Buchwald et al. · 2002 [cited by applicant]
US 6541639B2 · Zhou et al. · 2003 [cited by applicant]
US 6544559B2 · Mesens et al. · 2003 [cited by applicant]
US 6548493B1 · Robichaud et al. · 2003 [cited by applicant]
US 6552017B1 · Robichaud et al. · 2003 [cited by applicant]
US 6552024B1 · Chen et al. · 2003 [cited by applicant]
US 6603008B1 · Ando et al. · 2003 [cited by applicant]
US 6699852B2 · Robichaud et al. · 2004 [cited by applicant]
US 6713471B1 · Robichaud et al. · 2004 [cited by applicant]
US 6759554B2 · Buchwald et al. · 2004 [cited by applicant]
US 6762329B2 · Marcoux et al. · 2004 [cited by applicant]
US 6828314B2 · Frank et al. · 2004 [cited by applicant]
US 6849619B2 · Robichaud et al. · 2005 [cited by applicant]
US 6849640B2 · Ennis et al. · 2005 [cited by applicant]
US 6867298B2 · Buchwald et al. · 2005 [cited by applicant]
US 6888032B2 · Buchwald et al. · 2005 [cited by applicant]
US 6946560B2 · Buchwald et al. · 2005 [cited by applicant]
US 7026498B2 · Buchwald et al. · 2006 [cited by applicant]
US 7071186B2 · Robichaud et al. · 2006 [cited by applicant]
US 7109339B2 · Lee et al. · 2006 [cited by applicant]
US 7115784B2 · Buchwald et al. · 2006 [cited by applicant]
US 7183282B2 · Robichaud et al. · 2007 [cited by applicant]
US 7223879B2 · Buchwald et al. · 2007 [cited by applicant]
US RE39679E · Robichaud et al. · 2007 [cited by applicant]
US RE39680E · Robichaud et al. · 2007 [cited by applicant]
US 7238690B2 · Robichaud et al. · 2007 [cited by applicant]
US 7247731B2 · Buchwald et al. · 2007 [cited by applicant]
US 7323608B2 · Buchwald et al. · 2008 [cited by applicant]
US 7375226B2 · Jolidon et al. · 2008 [cited by applicant]
US 7462641B2 · Igo et al. · 2008 [cited by applicant]
US 7517990B2 · Ito et al. · 2009 [cited by applicant]
US 7592454B2 · Lee et al. · 2009 [cited by applicant]
US 7614727B2 · Hori · 2009 [cited by applicant]
US 7645752B2 · McDevitt et al. · 2010 [cited by applicant]
US 7998971B2 · Barlow et al. · 2011 [cited by applicant]
US 8309722B2 · Tomesch et al. · 2012 [cited by applicant]
US 8309772B2 · Weiner et al. · 2012 [cited by applicant]
US 8414922B2 · Bryson et al. · 2013 [cited by applicant]
US 8461148B2 · Hollander · 2013 [cited by applicant]
US 8598119B2 · Mates et al. · 2013 [cited by applicant]
US 8603514B2 · Yang et al. · 2013 [cited by applicant]
US 8648077B2 · Tomesch et al. · 2014 [cited by applicant]
US 8652378B1 · Yang et al. · 2014 [cited by applicant]
US 8697700B2 · Surman et al. · 2014 [cited by applicant]
US 8779139B2 · Tomesch et al. · 2014 [cited by applicant]
US 8791138B2 · Seeman et al. · 2014 [cited by applicant]
US 8835459B2 · Kottayil et al. · 2014 [cited by applicant]
US 8900497B2 · Yang et al. · 2014 [cited by applicant]
US 8900498B2 · Yang et al. · 2014 [cited by applicant]
US 8906277B2 · Yang et al. · 2014 [cited by applicant]
US 8993572B2 · Mates et al. · 2015 [cited by applicant]
US 9108340B2 · Yang et al. · 2015 [cited by applicant]
US 9168258B2 · Mates et al. · 2015 [cited by applicant]
US 9199995B2 · Tomesch et al. · 2015 [cited by applicant]
US 9216175B2 · Amancha et al. · 2015 [cited by applicant]
US 9315504B2 · Tomesch et al. · 2016 [cited by applicant]
US 9371324B2 · Mates et al. · 2016 [cited by applicant]
US 9393192B2 · Yam et al. · 2016 [cited by applicant]
US 9427412B2 · Bryson et al. · 2016 [cited by applicant]
US 9428506B2 · Mates et al. · 2016 [cited by applicant]
US 9567327B2 · Xiong et al. · 2017 [cited by applicant]
US 9586960B2 · Tomesch et al. · 2017 [cited by applicant]
US 9616061B2 · Mates et al. · 2017 [cited by applicant]
US 9708322B2 · Li et al. · 2017 [cited by applicant]
US 9745300B2 · Mates et al. · 2017 [cited by applicant]
US 9751883B2 · Tomesch et al. · 2017 [cited by applicant]
US 9956227B2 · Vanover et al. · 2018 [cited by applicant]
US 10072010B2 · Li et al. · 2018 [cited by applicant]
US 10077267B2 · Mates et al. · 2018 [cited by applicant]
US 10117867B2 · Mates et al. · 2018 [cited by applicant]
US 10716786B2 · Li et al. · 2020 [cited by applicant]
US 11124514B2 · Mates et al. · 2021 [cited by applicant]
US RE48839E · Mates et al. · 2021 [cited by applicant]
US 11292793B2 · Peddy et al. · 2022 [cited by applicant]
US 11311536B2 · Li et al. · 2022 [cited by applicant]
US 11331316B2 · Li et al. · 2022 [cited by applicant]
US 11376249B2 · Li et al. · 2022 [cited by applicant]
US 11407751B2 · Tomesch et al. · 2022 [cited by applicant]
US 11427587B2 · Li et al. · 2022 [cited by applicant]
US 11560382B2 · Mates et al. · 2023 [cited by applicant]
US 11680065B2 · Li et al. · 2023 [cited by applicant]
US 11690842B2 · Li et al. · 2023 [cited by applicant]
US 11723909B2 · Yao et al. · 2023 [cited by applicant]
US 11759465B2 · Kass et al. · 2023 [cited by applicant]
US 11806347B2 · Li · 2023 [cited by examiner]
US 11806348B2 · Li et al. · 2023 [cited by applicant]
US 11957791B2 · Li et al. · 2024 [cited by applicant]
US 11980617B2 · Snyder et al. · 2024 [cited by applicant]
US 12070459B2 · Li et al. · 2024 [cited by applicant]
US 12090155B2 · Mates et al. · 2024 [cited by applicant]
US 12128043B2 · Li et al. · 2024 [cited by applicant]
US 20010008942A1 · Buchwald et al. · 2001 [cited by applicant]
US 20040034015A1 · Robichaud et al. · 2004 [cited by applicant]
US 20040092534A1 · Yam et al. · 2004 [cited by applicant]
US 20040127482A1 · Robichaud et al. · 2004 [cited by applicant]
US 20040142970A1 · Chung et al. · 2004 [cited by applicant]
US 20040180875A1 · Lee et al. · 2004 [cited by applicant]
US 20040186136A1 · Alken et al. · 2004 [cited by applicant]
US 20040209864A1 · Robichaud et al. · 2004 [cited by applicant]
US 20050166771A1 · Gygi et al. · 2005 [cited by applicant]
US 20050222209A1 · Zeldis et al. · 2005 [cited by applicant]
US 20050222238A1 · Alken · 2005 [cited by applicant]
US 20060178362A1 · Robichaud et al. · 2006 [cited by applicant]
US 20060205787A1 · Muller et al. · 2006 [cited by applicant]
US 20070082929A1 · Gant et al. · 2007 [cited by applicant]
US 20070197695A1 · Potyen et al. · 2007 [cited by applicant]
US 20080069885A1 · Mesens et al. · 2008 [cited by applicant]
US 20080132552A1 · Kleinman et al. · 2008 [cited by applicant]
US 20080280941A1 · Lourtie · 2008 [cited by applicant]
US 20090076159A1 · Czarnik · 2009 [cited by applicant]
US 20090209608A1 · Czarnik · 2009 [cited by applicant]
US 20100113781A1 · Tomesch et al. · 2010 [cited by applicant]
US 20100137429A1 · Yoneda et al. · 2010 [cited by applicant]
US 20100159033A1 · Gant et al. · 2010 [cited by applicant]
US 20110071080A1 · Mates et al. · 2011 [cited by applicant]
US 20110112105A1 · Tomesch et al. · 2011 [cited by applicant]
US 20120196814A1 · Gong et al. · 2012 [cited by applicant]
US 20130202692A1 · Mates et al. · 2013 [cited by applicant]
US 20140210117A1 · Friesen et al. · 2014 [cited by applicant]
US 20150004237A1 · Edgar et al. · 2015 [cited by applicant]
US 20150031804A1 · Shiramizu et al. · 2015 [cited by applicant]
US 20150072964A1 · Mates et al. · 2015 [cited by applicant]
US 20150079172A1 · Mates et al. · 2015 [cited by applicant]
US 20150080404A1 · Mates et al. · 2015 [cited by applicant]
US 20160235720A1 · Foster et al. · 2016 [cited by applicant]
US 20160310502A1 · Vanover et al. · 2016 [cited by applicant]
US 20160354315A1 · Li · 2016 [cited by applicant]
US 20170114037A1 · Davis et al. · 2017 [cited by applicant]
US 20170183350A1 · Mates et al. · 2017 [cited by applicant]
US 20170189398A1 · Mates et al. · 2017 [cited by applicant]
US 20170283417A1 · Li et al. · 2017 [cited by applicant]
US 20170319580A1 · Yao et al. · 2017 [cited by applicant]
US 20180044337A1 · Tomesch et al. · 2018 [cited by applicant]
US 20180200256A1 · Vanover et al. · 2018 [cited by applicant]
US 20190071445A1 · Li et al. · 2019 [cited by applicant]
US 20190183888A1 · Mates et al. · 2019 [cited by applicant]
US 20190211015A1 · Mittelman et al. · 2019 [cited by applicant]
US 20190231780A1 · Yao et al. · 2019 [cited by applicant]
US 20200157100A1 · Li · 2020 [cited by applicant]
US 20210008065A1 · Li et al. · 2021 [cited by applicant]
US 20210315891A1 · Li et al. · 2021 [cited by applicant]
US 20230312573A1 · Li et al. · 2023 [cited by applicant]
US 20230372336A1 · Dutheil et al. · 2023 [cited by applicant]
EP 0058481 · 1982 [cited by applicant]
EP 0856508 · 1998 [cited by applicant]
EP 0976732 · 2000 [cited by applicant]
EP 1245553 · 2002 [cited by applicant]
EP 1254884 · 2002 [cited by applicant]
EP 1539115 · 2005 [cited by applicant]
EP 1564671 · 2005 [cited by applicant]
GB 1476087 · 1977 [cited by applicant]
GB 2145422 · 1985 [cited by applicant]
RU 2465267 · 2012 [cited by applicant]
WO WO1994024125 · 1994 [cited by applicant]
WO WO1995013814 · 1995 [cited by applicant]
WO WO1995026325 · 1995 [cited by applicant]
WO WO1998015515 · 1998 [cited by applicant]
WO WO1998043956 · 1998 [cited by applicant]
WO WO1999043643 · 1999 [cited by applicant]
WO WO2000002887 · 2000 [cited by applicant]
WO WO2000035419 · 2000 [cited by applicant]
WO WO2000048610 · 2000 [cited by applicant]
WO WO2000064899 · 2000 [cited by applicant]
WO WO2000077001 · 2000 [cited by applicant]
WO WO2000077002 · 2000 [cited by applicant]
WO WO2000077010 · 2000 [cited by applicant]
WO WO2002059129 · 2002 [cited by applicant]
WO WO2002085838 · 2002 [cited by applicant]
WO WO2003014118 · 2003 [cited by applicant]
WO WO2004010981 · 2004 [cited by applicant]
WO WO2004013094 · 2004 [cited by applicant]
WO WO2004039788 · 2004 [cited by applicant]
WO WO2004045668 · 2004 [cited by applicant]
WO WO2004056324 · 2004 [cited by applicant]
WO WO2005030214 · 2005 [cited by applicant]
WO WO2006034187 · 2006 [cited by applicant]
WO WO2006081251 · 2006 [cited by applicant]
WO WO2006081332 · 2006 [cited by applicant]
WO WO2007025103 · 2007 [cited by applicant]
WO WO2007030108A1 · 2007 [cited by applicant]
WO WO2007084841 · 2007 [cited by applicant]
WO WO2008112280 · 2008 [cited by applicant]
WO WO2009017836 · 2009 [cited by applicant]
WO WO2009100324 · 2009 [cited by applicant]
WO WO2009114181 · 2009 [cited by applicant]
WO WO2009145900 · 2009 [cited by applicant]
WO WO2011133224 · 2011 [cited by applicant]
WO WO2013155504 · 2013 [cited by applicant]
WO WO2013155505 · 2013 [cited by applicant]
WO WO2013155506 · 2013 [cited by applicant]
WO WO2014110322 · 2014 [cited by applicant]
WO WO2014145192 · 2014 [cited by applicant]
WO WO2015085004 · 2015 [cited by applicant]
WO WO2015154025 · 2015 [cited by applicant]
WO WO2015154030 · 2015 [cited by applicant]
WO WO2015191554 · 2015 [cited by applicant]
WO WO2017117514 · 2017 [cited by applicant]
WO WO2017132408 · 2017 [cited by applicant]
WO WO2017165755 · 2017 [cited by applicant]
WO WO2017165843 · 2017 [cited by applicant]
WO WO2017172784 · 2017 [cited by applicant]
WO WO2018031535 · 2018 [cited by applicant]
WO WO2018106916 · 2018 [cited by applicant]
WO WO2018175969 · 2018 [cited by applicant]
WO WO2018189646 · 2018 [cited by applicant]
WO WO2019102240 · 2019 [cited by applicant]
“Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression,” ClinicalTrials.gov, 6 pages, Nov. 9, 2015. [cited by applicant]
“Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar,” ClinicalTrials.gov (Identifier: NCT02600494), 5 pages, (2015). [cited by applicant]
“Study of a Novel Antipsychotic ITI-007 in Schizophrenia,” Clinical Trials.gov, 6 pages, Dec. 26, 2011. [cited by applicant]
Aiken, “An Overview of Atypical Antipsychotics for Bipolar Depression,” published on Jan. 3, 2020 at https://www.psychiatrictimes.com/view/overview-atypical-antipsychotics-bipolar-depression, 11 pages. [cited by applicant]
Angst et al. “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode”, [cited by applicant]
Baille, T.A., “The Use of Stable Isotopes in Pharmacological Research,” [cited by applicant]
Balbach, et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg-approach’,” [cited by applicant]
Barman et al., “Newer Antipsychotics: Brexpiprazole, Cariprazine, and Lumateperone: A Pledge or Another Unkept Promise?,” World J. Psychiatr., vol. 11, No. 12, p. 1228-1238, (2021). [cited by applicant]
Bechtold et al., “Circadian Dysfunction in Disease,” [cited by applicant]
Borghans et al., “Animal Models for Posttraumatic Stress Disorder: An Overview of What is Used in Research,” [cited by applicant]
Bremner, et al., “Neuroimaging of Posttraumatic Stress Disorder”, [cited by applicant]
Browne, T.R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,” [cited by applicant]
Bryan-Lluka, et al., “Potencies of Haloperidol Metabolites as Inhibitors of the Human Noradrenaline, Dopamine and Serotonin Transporters in Transfected COS-7 Cells,” [cited by applicant]
Byrn, et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” [cited by applicant]
Calabrese et al., “Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial,” Am J Psychiatry, vol. 178, No. 12, p… [cited by applicant]
Cherrah, et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,” [cited by applicant]
Correll et al., “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial,” JAMA Psychiatry, vol. 77, No. 4, p. 349-358 (2020). [cited by applicant]
Coyle et al., “Beyond the Dopamine Receptor: Novel Therapeutic Targets for Treating Schizophrenia,” Dialogues Clin. Neurosci., vol. 12, No. 3, p. 359-382 (2010). [cited by applicant]
Darmani, et al., “Do Functional Relationships Exist Between 5-HT [cited by applicant]
Davis, et al., “ITI-007 demonstrates brain occupancy at serotonin 5-HT [cited by applicant]
Davis, et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,” [cited by applicant]
Davis et al., “ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders,” Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014 (2014) (poster presentation). [cited by applicant]
Davis et al., “Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia,” The Journal of Prevention of Alzheimer's Disease, 2(4):302 (2015) (Clinical Tr… [cited by applicant]
Davis, et al., “Lumateperone (ITI-007), A Novel Drug in Development for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease: Rationale and Clinical Design,” The Journal of Prevention of A… [cited by applicant]
Docherty et al., “Effect of Aripiprazole Versus Haloperidol on PANSS Prosocial Items in Early-Episode Patients with Schizophrenia,” Schizophrenia Res., vol. 120, p. 199-203 (2010). [cited by applicant]
Dyck, et al., “Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An In Vivo Study,” [cited by applicant]
Edinoff et al., “Lumateperone for the Treatment of Schizophrenia,” Psychopharmacology Bulletin, vol. 50, No. 4, p. 32-59 (2020). [cited by applicant]
Ellenbroek et al., “Animal Models for the Negative Symptoms of Schizophrenia,” Behavioural Pharmacology, vol. 11, pp. 223-233, (2000). [cited by applicant]
Fletcher et al., “Perceiving is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia,” [cited by applicant]
Foster, A.B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,” [cited by applicant]
Foster, et al., “Acetylcholinesterase Inhibitors Reduce Spreading Activation in Dementia,” [cited by applicant]
Foster et al., “Emerging Approaches for Treatment of Schizophrenia: Modulation of Cholinergic Signaling,” Discov. Med., vol. 14, No. 79, p. 413-420 (2012). [cited by applicant]
Friedman, M.J.., “Current and Future Drug Treatment for Posttraumatic Stress Disorder Patients”, Psychiatric Annals Journal, vol. 28, No. 8, pp. 464-468, (1998). [cited by applicant]
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,” [cited by applicant]
Gramigna, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages. [cited by applicant]
Hackam, et al., “Translation of Research Evidence from Animals to Humans,” [cited by applicant]
Harvey, et al., “Serotonin and Stress: Protective or Malevolent Actions in the Biobehavioral Response to Repeated Trauma?,” [cited by applicant]
Haskins, N.J., “The Application of Stable Isotopes in Biomedical Research,” [cited by applicant]
Helfer et al., “Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis,” Am. J. Psychiatry, vol. 173, No. 9, p. 876-886 (2016). [cited by applicant]
Hlavinka, “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage/psy… [cited by applicant]
Honma, S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride: Liberation of Deuterium from the Piperidine Ring during Hydroxylation,” [cited by applicant]
Howes et al., “Glutamate and Dopamine in Schizophrenia: An Update for the 21st Century,” J. Psychopharmacol., vol. 29, No. 2, p. 97-115 (2015). [cited by applicant]
Howland, R.H., “Deuterated Drugs,” Journal of Psychosocial Nursing and Mental Health Services, 53(9): 13-16 (2015). [cited by applicant]
Izrayelit, L., “Schizoaffective Disorder and PTSD Successfully Treated With Olanzapine and Supportive Psychotherapy”, [cited by applicant]
Johnson et al., “Serotonin receptor activity is necessary for olfactory learning and memory in [cited by applicant]
Jordan, V.C., “Tamoxifen: A Most Unlikely Pioneering Medicine,” [cited by applicant]
Juorio, A.V., et al., “Effects of Acute and Chronic Phenelzine on Regional Monoamine Metabolism in Rats and its Potentiation by Deuterium Substitution,” [cited by applicant]
Kahn et al., “Residual Symptoms of Schizophrenia. What are Realistic Treatment Goals? Lingering Symptoms Require you to Evaluate Pharmacotherapy and Offer Psychosocial Interventions,” [cited by applicant]
Kay, et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,” [cited by applicant]
Kessler, et al., “Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication,” [cited by applicant]
Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,” Bioorganic & Medicinal Chemistry, vol. 11, pp. 717-722, p. 718 Table 1, (2003). [cited by applicant]
Koppel, et al., “Optimal Treatment of Alzheimer's Disease Psychosis: Challenges and Solutions,” [cited by applicant]
Krystal et al., “Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related Ptsd: A Randomized Trial,” JAMA, vol. 306, No. 5, pp. 493-502, (2011). [cited by applicant]
Kumar et al., “Lumateperone: A New Treatment Approach for Neuropsychiatric Disorders,” Drugs of Today, vol. 54, No. 12, p. 713-719, (2018). [cited by applicant]
Lammers et al., “Risperidone Long-acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada,” [cited by applicant]
Lee, et al. “Novel, Highly Potent, Selective 5-HT [cited by applicant]
Li, et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,” [cited by applicant]
Lieberman, et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” [cited by applicant]
Lin, et al., “Dosage and Duration of Antipsychotic Treatment in Demented Outpatients with Agitation or Psychosis,” [cited by applicant]
Lipschitz, et al., “Childhood Posttraumatic Stress Disorder: A Review of Neurobiologic Sequelae,” [cited by applicant]
Liriano et al., “Ketamine as treatment for post-traumatic stress disorder: a review.” Drugs in Context, vol. 8, 7 pages (2019). [cited by applicant]
Madhusoodanan, et al., “Pharmacological Management of Behavioral Symptoms Associated with Dementia,” [cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” [cited by applicant]
Marek et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003. vol. 28, pp. 402-412. (Year: 2003). [cited by applicant]
McConnell et al., “Modified-Release Oral Drug Delivery,” Aulton's Pharmaceutics, Chapter 31, pp. 550-565 (2013). [cited by applicant]
McIntyre et al., “Rapid-acting Antidepressants in Psychiatry: Psychedelics, Episodic Treatments, Innovation, and Clarion Call for Methodologic Rigor in Drug Development,” Expert Opinion on Drug Safety, vol. 21, No. 6, p… [cited by applicant]
Medisorb Fact Sheet in Medisorb Microspheres Technology (Jan. 2009) at https://static.secure.website/wscfus/6472891/uploads/Medisorb.pdf (retrieved from the internet May 18, 2020) (Year: 2009). [cited by applicant]
Meeter et al., “Effect of 5-HT on Memory and the Hippocampus: Model and Data,” [cited by applicant]
Minzenberg et al., “Modafinil: A Review of Neurochemical Actions and Effects on Cognition,” Neuropsychopharmacology, vol. 33, pp. 1477-1502 (2008). [cited by applicant]
Mohamed, et al., “Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-guided Drug Selection,” [cited by applicant]
Möller et al., “Pharmacological Treatment of Negative Symptoms in Schizophrenia,” Eur. Arch. Psychiatry Clin. Neurosci., vol. 265, p. 567-578 (2015). [cited by applicant]
Müller et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,” [cited by applicant]
Nihon rounen igaku zasshi, vol. 48, No. 3, pp. 195-204, (2011 nen). Partial English translation only, 2 pages. [cited by applicant]
Noble et al., “The Opioid Receptors as Targets for Drug Abuse Medication,” British Journal of Pharmacology, vol. 172, pp. 3964-3979, (2015); DOI: 10.1111/bph.13190. [cited by applicant]
O'Gorman, et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” Poster P.1.g.038, European College of Neuropsychopharmacology (ECNP)… [cited by applicant]
O'Hara et al., “Serotonin Transporter Polymorphism, Memory, and Hippocampal Volume in the Elderly: Association and Interaction with Cortisol,” [cited by applicant]
Olivier et al., “Serotonin transporter deficiency in rats contribute to impaired object memory,” [cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4… [cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”, [cited by applicant]
Pieniaszek, et al., “Moricizine Bioavailability via Simultaneous Dual, Stable Isotope Administration: Bioequivalence Implications,” [cited by applicant]
Pine et al., “Dopamine, Time, and Impulsivity in Humans,” [cited by applicant]
Puig et al., “Serotonin and Prefrontal Cortex Function: Neurons, Networks, and Circuits,” [cited by applicant]
Rackova, et al., “Free Radical Scavenging and Antioxidant Activities of Substituted Hexahydropyridoindoles. Quantitative Structure-Activity Relationships.” [cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,” [cited by applicant]
Ramaswamy et al., “Failed Efficacy of Ziprasidone in the Treatment of Post-Traumatic Stress Disorder,” [cited by applicant]
Reynolds et al., “Longitudinal Change in Memory Performance Associated with HTR2A Polymorphism,” [cited by applicant]
Rummel et al., “Antidepressants as Add-on Treatment to Antipsychotics for People with Schizophrenia and Pronounced Negative Symptoms: A Systematic Review of Randomized Trials,” Schizophrenia Res., vol. 80, p. 85-97 (200… [cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Alzheimer's & Dementia 14(7) (Suppl.): p. 678-79 (2018) (Alzheimer's Assoc. International… [cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Poster P2-032, Alzheimer's Assoc. International Conference 2018 (2018). [cited by applicant]
Savjani, et al., “Drug Solubility: Importance and Enhancement Techniques,” [cited by applicant]
Schennach et al., “What Are Residual Symptoms in Schizophrenia Spectrum Disorder? Clinical Description and 1-year Persistence Within a Naturalistic Trial,” [cited by applicant]
Seishinkei Shi, vol. 110, No. 7, pp. 557-584, (2008). Partial English translation only. [cited by applicant]
Semla et al., “Off-Label Prescribing of Second-Generation Antipsychotics to Elderly Veterans with Posttraumatic Stress Disorder and Dementia,” [cited by applicant]
Sepehry et al., “Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia: A Meta-Analysis,” J. Clin. Psychiatry, vol. 68, No. 4, p. 604-610 (2007). [cited by applicant]
Silver et al., “Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?,” Neurotherapeutics, vol. 6, p. 8… [cited by applicant]
Singh et al., “Efficacy of Antidepressants in Treating the Negative Symptoms of Chronic Schizophrenia: Meta-Analysis,” The British Journal of Psychiatry, vol. 197, p. 174-179 (2010). [cited by applicant]
Singhal, et al., “Drug Polymorphism and Dosage Form Design: A Practical Perspective,” [cited by applicant]
Snyder, et al., “Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission,” [cited by applicant]
Southwick, et al., “Neuroendocrine Alterations in Posttraumatic Stress Disorder,” [cited by applicant]
Suzuki et al., “Comparison of Nicotinamide, Ethyluirea and Polyethylene Glycol as Carriers for Nifedipine Solid Dirperssion Systems.” Chemical and Pharmaceutical Bulletin, vol. 45, No. 10, pp. 1688-1693, (1997). [cited by applicant]
Timmins, G.S., “Deuterated drugs: where are we now?” Expert Opinion on Therapeutic Patents, 1-9 (2014). [cited by applicant]
Tohen et al., “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression,” Arch Gen Psychiatry, vol. 60, pp. 1079-1088, (2003). [cited by applicant]
Tung, R., “The Development of Deuterium-Containing Drugs,” [cited by applicant]
Vanover et al., Abstracts of the 13th International Congress on Schizophrenia (ICOSR) (Apr. 2-6, 2011), Schizophrenia Bull. 37 Suppl. 1., p. 325 (Mar. 2011). [cited by applicant]
Vanover et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,” International Clinical Psychopharamcology, vol. 26, e56, 1 page, (2011). [cited by applicant]
Vanover, et al., “A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate,” Abstract presented at the Ameri… [cited by applicant]
Vanover, et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,” Neuropsychopharmacology 44:598-605, (2019). [cited by applicant]
Vanover, K., et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,” International Clinical Psychopharamcology, vol. 26, e56, 1 page, (2011). [cited by applicant]
Vloeberghs et al., “Altered Circadian Locomotor Activity in APP23 Mice: A Model for BPSD Disturbances,” [cited by applicant]
Vyas et al., “An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia,” [cited by applicant]
Wang et al., “Rapid-acting Antidepressants Targeting Modulation of the Glutamatergic System: Clinical and Preclinical Evidence and Mechanisms,” General Psychiatry, vol. 35, No. e100922, 6 pages, (2022). [cited by applicant]
Warner-Schmidt et al., “Antidepressant Effects of Selective Serotonin Reuptake Inhibitors (SSRIs) are Attenuated by Antiinflammatory Drugs in Mice and Humans,” PNAS, vol. 108, No. 22, pp. 9262-9267, (2011). [cited by applicant]
Wennogle, et al., “Activation of NMDA and AMPA Receptors by Lumateperone (ITI-007): Implications for Antidepressant Activity,” Abstract presented at the 2017 Collegium Internationale Neuro-Psychopharmacologicum (CINP) T… [cited by applicant]
Weschules, et al., “Acetylcholinesterase Inhibitor and N-Methyl- [cited by applicant]
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,” [cited by applicant]
Yudofsky, et al., “Propranolol in the Treatment of Rage and Violent Behavior in Patients with Chronic Brain Syndromes,” [cited by applicant]
Zhang et al., “The Role of Serotonin 5-HT2A Receptors in Memory and Cognition,” Front. Pharmacol., vol. 6, No. 225, pp. 1-17, (2015); DOI: 10.3389/fphar.2015.00225. [cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N… [cited by applicant]
Bastin, R. et al., “Salt Selection and Optimized Procedures for Pharmaceutical New Chemical Entities,” Organic Process and Research Development, vol. 4, No. 5, pp. 427-435, (2000). [cited by applicant]
Dimmit et al., “Low Drug Doses May Improve Outcomes in Chronic Disease,” Viewpoint, vol. 191, No. 9, (2009). [cited by applicant]
Harvey, P. et al., “Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patient with Schizophrenia,” Abstract presented at the American Society of Clinical Psychopharmacology (ASCP) An… [cited by applicant]
Liu et al., “Progress in Deuterated Drugs,” Chemical Engineering Design Communications, vol. 42, No. 4, p. 199-238; English Abstract Only (2016). [cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study '302)”, Intra-Cellular Therapies, Press Release Date: Sep. 28, 2016, 8 p… [cited by applicant]
Press Release, “Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial With ITI-007 in Patients with Sleep Maintenance Insomnia.”, Intra-Cellular Therapies, Press Release Date: Mar. 10, 200… [cited by applicant]
Vanover, K. et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” European Neuropsychopharmacology, vol. 27, pp. S660-S661 (2017) (S… [cited by applicant]